TheraCyte Cell Encapsulation System IDE Slated For Second Quarter
This article was originally published in The Gray Sheet
Executive Summary
TheraCyte, Inc. plans to file an investigational device exemption with FDA during the second quarter for a Phase I study intended to evaluate the TheraCyte encapsulated cell technology implant system.
You may also be interested in...
Genzyme Spinning Off Surgical Division, Transferring NeuroCell In-House
Genzyme General plans to spin off its surgical products business into a separately traded company by the third quarter of 1999 in order to accelerate growth in both businesses, the Cambridge, Massachusetts-based firm announced March 4 in reporting 1998 year-end results.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.